Replies to post #146664 on Biotech Values

[DewDiligence]

Biotech-Partnership Buyouts

[Updated for AGN-MAPP.]


Many drug/biotech partnerships eventually result in buyout offers;
here are a few examples in descending order of buyout premium:

 Roche-MEMY  319%  
 PFE  -COLY  167%  
 PFE  -ICGN  150%  
 LLY  -SGXP  119%  
 PFE  -ENCY  118%  
 GSK  -HGSI   99%  
 NVS  -Spdel  94%  
 BMY  -MEDX   90%  
 BMY  -ZGEN   84%  
 BIIB -FACT   64% (outbid by ABT)  
 AGN  -MAPP   60% 
 JNJ  -CRXL   58%  
 LLY  -ICOS   54%  
 AMGN -ABGX   54%  
 BMY  -IMCL   51% (outbid by LLY)  
 MRK  -SGP    34%  
 AMGN -MITI   33% 

Who will be next?